by Rod Raynovich | Feb 18, 2011 | BIOgraph
On Feb.11 Optimer completed a 6M share offering of common stock at a price of $11.25 sh. and the stock has held up well despite the dilution. On February 7 the Company announced a deal with Astellas Pharmaceutical licensing off rights to their Fidaxomycin C.diff drug...
by Rod Raynovich | Feb 14, 2011 | 2024-25 Life Science Portfolios, BIOgraph
BIO CEO and Investor Conference Feb 14-15 Biotechnology stocks picked up some buying interest today from the BIO CEO Conference in NYC. CNBC provided some CEO clips from Exelixis (EXEL $10.58) up 7%, Onyxx(ONXX $36.28) up 0.28% and Optimer (OPTR $11.61) up 2.83%....
by Rod Raynovich | Feb 11, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Techs (QLD up 1.23%) outperformed biotechs today as Cisco bad news was forgotten. Biotech stocks treaded water today as all major ETF’s were flat. On the news front: Cephalon(CEPH $58.20) was down 3.17% on heavy volume as investors sold on there earnings report...
by Rod Raynovich | Feb 10, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biotechnology Rally Underway The NASDAQ market recovered from near 1% losses today caused by the Cisco(CSCO) earnings report and guidance. The NASDAQ is currently flat to slightly down at 2785 recovering from the 2760 level. Expectations that Egypt’s President...
by Rod Raynovich | Feb 9, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Life Sciences Market Remains Strong while M&A Provides Support As we enter the peak earnings season for many tools and device companies, initial reports would indicate that investor expectations are higher and stocks could have a bit of profit taking. Genomic...
by Rod Raynovich | Feb 8, 2011 | BIOgraph
8.6X EBITA Too Rich for LBO Crowd-See Bloomberg article below Becton Dickinson(BDX) announced results for the fiscal first quarter ending Dec 31,2011 with a revenues of $1.842B a decrease of 1.4% from the prior year period.EPS was $1.37(with a tax benefit) compared...
by Rod Raynovich | Feb 7, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Healthcare and Biotechnology stocks are underperforming the S&P YTD-Medical Devices and Equipment are a bright spot up over 4% YTD. The Q4 2010 momentum in biotech stocks has ebbed in 2011 as the broad market rally continues. The S&P is up 5% YTD while the...
by Rod Raynovich | Jan 26, 2011 | BIOgraph
The melt-up resumes. Everyone talks about the really big correction but all we get is a measly 2-3% hit then onward and upward. Metals and materials were ~2% winners today and the NAZ was up 0.75%. Titanium (TIE) was up 7.9 % . What’s with that? Although...
by Rod Raynovich | Jan 25, 2011 | BIOgraph
Biologics for Treatment of Cancer and Prevention of Infectious Disease Amgen(AMGN) and Biovex said today that both Boards approved the sale of privately held Biovex for $425M with milestone payments as much as $525M. The Biovex lead product OncoVex, an oncolytic...
by Rod Raynovich | Jan 24, 2011 | BIOgraph, Reading List
Will the GOP cut the NIH budget? Turf battles at the Institutes to follow. Who knew there were only two breakthroughs in mental health drugs: Thorazine and Lithium? Federal Research Center Will Help Develop Medicines – NYTimes.com Most experts believe the PET...
